文献速递胸部肿瘤支持与姑息治疗

转移性癌症患者清晨免疫检查点阻断与总生存:一项深入的时间治疗学研究

Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study.
PubMed 文献 · Eur J Cancer · 2024-01-22

该回顾性队列研究纳入2015年11月至2021年3月在法国Centre Leon Bérard接受帕博利珠单抗、纳武利尤单抗、阿替利珠单抗、度伐利尤单抗或阿维鲁单抗治疗的361例转移性或局部晚期实体瘤患者,评估免疫检查点阻断(ICB)输注时间与生存、肿瘤反应及毒性的关联。清晨输注与较下午输注改善总生存相关(中位30.3 vs 15.9个月,p=0.0024;HR 1.56 [1.17-2.1],p=0.003),且与体力状态(PS)存在强交互作用。作者结论认为清晨ICB输注与PS0-1患者总生存、反应及毒性增加相关,需前瞻性随机试验确认。

要点

  • 清晨ICB输注较下午与总生存改善相关(中位30.3 vs 15.9个月,p=0.0024)。
  • PS0-1患者中,清晨输注组中位OS 36.7 vs 21.3个月(p=0.023)。
  • PS0-1患者中,清晨输注组部分/完全缓解率58% vs 41%(p=0.027)。

核心结论

  • 在PS0-1患者中,清晨ICB输注与日内较晚输注相比,与总生存、缓解及毒性增加相关。
  • 作者指出需前瞻性随机试验来确认这项回顾性研究的结果。

研究设计与样本

  • 回顾性研究,纳入2015年11月至2021年3月在法国Centre Leon Bérard接受帕博利珠单抗、纳武利尤单抗、阿替利珠单抗、度伐利尤单抗或阿维鲁单抗(单药或联合化疗)治疗的转移性或局部晚期实体瘤患者。
  • 共分析361例患者,其中80%为非小细胞肺癌,平均[SD]年龄63[11]岁,女性占39%,首次输注时83%为PS0-1,19%接受联合化疗。

主要发现

  • ICB输注时间范围为07:25至17:21,最佳上午/下午截断点为11:37。
  • 上午输注较下午输注与总生存增加相关(中位30.3 vs 15.9个月,p=0.0024;HR 1.56 [1.17-2.1],p=0.003)。
  • 发现强的PS-输注时间交互作用(PS0-1患者,HR=1.53 [1.10-2.12],p=0.011;PS2-3患者,HR=0.50 [0.25-0.97],p=0.042)。
  • PS0-1患者中,上午输注组较下午输注组总生存增加(中位36.7 vs 21.3个月,p=0.023),部分/完全缓解率(58% vs 41%,p=0.027)及1-3级毒性(49% vs 34%,p=0.028)均增加。
  • 日内最差输注时间(估计为13:36 [12:48-14:23])与清晨输注之间的死亡风险比为4.8([2.3-10.1],p=0.008)。

关键数值与推荐

  • PS0-1患者上午 vs 下午:中位OS 36.7 vs 21.3个月,p=0.023;部分/完全缓解率58% vs 41%,p=0.027;1-3级毒性49% vs 34%,p=0.028。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性研究。
  • 作者指出需前瞻性随机试验来确认这项回顾性研究的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Recent retrospective studies suggest potential large patient's benefit through proper timing of immune checkpoint blockers (ICB). The association between ICB treatment timing and patient survival, neoplastic response and toxicities was investigated, together with interactions with performance status (PS) and sex. METHODS: A cohort of patients with metastatic or locally advanced solid tumors, who received pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab, alone or with concomitant chemotherapy, between November 2015 and March 2021, at the Centre Leon Bérard (France), was retrospectively studied. RESULTS: 361 patients were investigated (80% non-small cell lung cancer patients, mean [SD] age: 63 [11] years, 39% of women, 83% PS0-1 at first infusion, 19% received concomitant chemotherapy). ICB were administered from 07:25 to 17:21 and optimal morning/afternoon cut-off was 11:37. Morning infusions were associated with increased OS as compared to afternoon (median 30.3 vs 15.9 months, p = 0.0024; HR 1.56 [1.17-2.1], p = 0.003). A strong PS-timing interaction was found (PS0-1 patients, HR=1.53 [1.10-2.12], p = 0.011; PS2-3 patients, HR=0.50 [0.25-0.97], p = 0.042). Morning PS0-1 patients displayed increased OS (median 36.7 vs 21.3 months, p = 0.023), partial/complete response rate (58% vs 41%, p = 0.027), and grade1-3 toxicities (49% vs 34%, p = 0.028). Mortality risk ratio between infusions at worst time-of-day, estimated at 13:36 [12:48-14:23], and in early morning was equal to 4.8 ([2.3-10.1], p = 0.008). Timing differences in toxicities resulted significant only in female patients (women vs men: p < 0.001 vs 0.4). CONCLUSIONS: Early morning ICB infusion was associated with increased OS, response, and toxicities in patients with PS0-1 as compared to later infusions within the day. Prospective randomized trials are needed to confirm this retrospective study.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Catozzi S, Assaad S, Delrieu L, et al. Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study. Eur J Cancer. 2024. PMID: 38301362. doi:10.1016/j.ejca.2024.113571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。